Self-administering peptides purchased outside of a licensed medical setting carries significant risk dosing, sourcing, and protocol all matter
At admission, she could not get out of bed, had just gotten off a ventilator, had many medications that needed to be administered, was a heavy woman, and was anxious
Researchers should add one compound at a time, assess tolerance, and avoid the temptation to implement complex protocols immediately
A phase III clinical trial called STEP 1 (Semaglutide treatment effect in people with obesity) involving 1,961 participants with obesity found that weekly subcutaneous injections of semaglutide, in addition to lifestyle intervention, produced an average of 14.9% body weight loss compared with 2.4% in those who received placebo after 68 weeks[8]